Key result
A 50% higher IL-6 level at 2 or 3 months was associated with increased mortality in anticoagulated patients with atrial fibrillation.
Why the study?
Interleukin-6 is associated with mortality in AF, but whether repeated measurements improve prognostication for stroke, systemic embolism, major bleeding, and mortality was unknown.
Cohort (n=7,389)
Yes
Answers are grounded in this paper and cite their sources.
IL-6 elevation signals higher mortality risk in anticoagulated AF; hypothesis-generating and should not yet change practice.
BACKGROUND: The inflammatory biomarker interleukin-6 (IL-6) is associated with mortality in atrial fibrillation (AF). OBJECTIVE: To investigate if repeated IL-6 measurements improve the prognostication for stroke or systemic embolism, major bleeding, and mortality in anticoagulated patients with AF. METHODS: IL-6 levels by ELISA were measured at study entry and at 2 months in 4830 patients in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial with 1.8 years median follow-up. In the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial, IL-6 was measured at study entry, 3, 6, and 12 months in 2559 patients with 2.0 years median follow-up. Associations between a second IL-6 measurement and outcomes, adjusted for baseline IL-6, clinical variables, and other cardiovascular biomarkers, were analyzed by Cox regression. RESULTS: Median IL-6 levels were 2.0 ng/L (interquartile range [IQR] 1.30-3.20) and 2.10 ng/L (IQR 1.40-3.40) at the two time-points in ARISTOTLE, and, in RE-LY, 2.5 ng/L (IQR 1.6-4.3), 2.5 ng/L (IQR 1.6-4.2), 2.4 ng/L (IQR 1.6, 3.9), and 2.4 ng/L (IQR 1.5, 3.9), respectively. IL-6 was associated with mortality; hazard ratios per 50% higher IL-6 at 2 or 3 months, respectively, were 1.32 (95% confidence interval, 1.23-1.41; P < .0001) in ARISTOTLE, and 1.11 (1.01-1.22, P = .0290) in RE-LY; with improved C index from 0.74 to 0.76 in ARISTOTLE, but not in the smaller RE-LY cohort. There were no consistent associations with second IL-6 and stroke or systemic embolism, or major bleeding. CONCLUSIONS: Persistent systemic inflammatory activity, assessed by repeated IL-6 measurements, is associated with mortality independent of established clinical risk factors and other strong cardiovascular biomarkers in anticoagulated patients with AF.
No takes yet. Share an insight, caveat, or question.
Aulin et al. (2020) conducted a cohort in Atrial fibrillation (n=7,389). 50% higher IL-6 at 2 or 3 months vs. Lower IL-6 levels was evaluated on Mortality (HR 1.32, 95% CI 1.23-1.41, p=<.0001). A 50% higher IL-6 level at 2 or 3 months was associated with increased mortality in anticoagulated patients with atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: